Skip to main content
Premium Trial:

Request an Annual Quote

Agilent to Provide Service and Support for NimbleGen as Roche Shutters Microarray Business

NEW YORK (GenomeWeb News) – Agilent Technologies and Roche today announced that Agilent will provide service to NimbleGen microarray customers as Roche shutters that business.

Researchers using NimbleGen microarrays for all applications can transition to Agilent arrays, effective immediately with minimal disruptions, the companies said. Because of the similarities of the two firms' technologies and products, Agilent microarrays can be run on the NimbleGen MS200 Microarray Scanner.

"With Agilent as a leading global supplier of microarray technology, we are convinced researchers will be provided with the highest compatibility to NimbleGen products and services, and believe that they will continue to receive the exceptional service and support they have come to expect," Dan Zabrowski, head of Roche Applied Science, said in a statement.

"Our field service personnel are working directly with individual researchers to help convert their NimbleGen designs, and they will continue to provide enhanced service and support throughout the transition period and beyond," Robert Schueren, vice president and general manager of Agilent's Genomics Systems Division, added. "Additionally, Agilent is also enabling customers to read their arrays on NimbleGen scanners, eliminating the need to invest in capital equipment."

Financial and other terms of the agreement were not disclosed.

Roche decided to discontinue the NimbleGen microarray products in June and sought a buyer for the business, as GenomeWeb Daily News' sister publication BioArray News reported at the time.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.